Abbreviations	Definitions
NHL	Non-Hodgkin lymphoma
DLBCL	Diffuse large B-cell lymphoma
BL	Burkitt lymphoma
PMBCL	Primary mediastinal B-cell lymphoma
FL	Follicular lymphoma
MZL	Marginal zone lymphoma
ALK+	ALK-positive
ALCL	Anaplastic large cell lymphoma
LBL-T	T cell lymphoblastic lymphoma
LBL-B	B-cell lymphoblastic lymphoma
ID3	Inhibitor of DNA binding 3
BLL	Burkitt-like lymphoma
TCF3	Transcription Factor 3
ALK	Anaplastic lymphoma kinase gene
NPM	Nucleophosmin gene
ABDTRG	Absence of biallelic deletion of the TRG locusT cell receptor gamma
CNS	Central nervous system
RT	Radiotherapy
B-NHL	B-cell non-Hodgkin lymphoma
FDA	Food and Drug Administration
mAbs	Monoclonal antibodies
ICIs	Immune checkpoint inhibitors
ADCs	Antibody–drug conjugates
CAR	Chimeric antigen receptor
HDAC	Histone deacetylase
DNMT	DNA methyltransferase
IDH	Isocitrate dehydrogenase
Allo-HSCT	Allogenic hematopoietic stem-cell transplantation
Auto-ASCT	Autologous stem cell transplantation
CHOP	Cyclophosphamide, doxorubicin, vincristine, prednisone
allo-SCT	Allogenic stem cell transplantation
HDC/ASCT	High-dose chemotherapy supported by autologous stem cell transplantation
Bv	Brentuximab vedotin
BiAbs	Bispecific antibodies
scFv	Single-chain variable fragments
OS	Overall survival
R/R	Relapsed or refractory
MMAE	Monomethyl auristatin E
COG	Children Oncology Group
EFS	Event free survival
CR	Complete Response
PR	Partial response
IO	Inotuzumab ozogamicin
BCMA	B-cell maturation antigen
MCL	Mantle cell lymphoma
MRD	Minimal residual disease
HDACIs	Histone deacetylase inhibitors
GVHD	Graft-versus-host disease
EZH2	Enhancer of Zeste Homolog 2
GC	Germinal center
αKG	α-ketoglutarate
D-2HG	D-2-hydroxyglutarate
AML	Acute myeloid leukemia
BCL-2	B2 cell lymphoma protein
ORRs	Overall responses rates
LL	Lymphoblastic lymphoma
ALK	Anaplastic lymphoma kinase
BTK	Bruton’s tyrosine kinase
BCR	B-cell antigen receptor
RICE	Rituximab plus ifosfamide, carboplatin, and etoposide
CRu	Complete response unconfirmed
IVB	Bortezomib with ifosfamide/vinorelbine
BICE	Bortezomib, ifosfamide, carboplatin, and etoposide
OR	Overall response
mTOR	Mammalian targets of the rapamycin
PI3K	Protein-3-phosphoinositide kinase B
PFS	Progression-free survival
BeRT	Bendamustine + rituximab + temsirolimus
DNA	Deoxyribonucleic acid